Key figures

Fourth quarter, October 1 – December 31, Q4 2024 Group

(figures in parentheses refer to the corresponding period in the previous year)

  • Net sales amounted to 0 (0).
  • Other operating income amounted to 15,317 (11,580) TSEK.
  • Profit after tax amounted to 2,011 (-110,094) TSEK.
  • Earnings per share before and after dilution: 0.00 (-0.32) SEK.
  • Cash flow from operating activities was -6,447 (-1,954) TSEK.

 

Full year, January 1 – December 31, 2024 Group

(figures in parentheses refer to the corresponding period in the previous year)

  • Net sales amounted to 0 (0).
  • Other operating income amounted to 19,134 (11,748) thousand SEK.
  • Profit after tax amounted to –26,937 (-135,461) thousand SEK.
  • Earnings per share: -0.04 (-0.39) SEK.
  • Cash flow from operating activities was -27 946 (-25,548) thousand SEK.
  • Cash and cash equivalents as of December 31, 2024 were 15,734 (13,274) thousand SEK.
  •  

Significant events during the quarter

  • In October, warrants of series TO7 were exercised for new shares in
    Prolight. The exercise period ran from October 7 to October 18 and were
    exercised to approximately 96.4 percent. Prolight raised approximately
    SEK 12.6 million before issue costs.
  • Prolight was granted a European patent for the separation of plasma from whole
    blood within a fluidic consumable. The patent opens new potential business
    opportunities by incorporating the technology into other disposable fluidic
    systems
  • The first of thirty commercial prototype instruments for the Psyros system
    from partner G&H | ITL were delivered.
  • Prolight submitted a sixth patent application related to the Psyros system
    regarding the use of all types of fluorophores.

 

Significant events after the end of the period

  • Prolight received Notice of Intention to Grant for core Psyros patent from the European Patent Office (EPO), protecting the company’s single molecule counting POC technology.
  • Prolight receiveds second Notice of Intention to Grant from EPO for Psyros
    technololgy. This application is an extension to the core application.

Subscribe